Study of JAB-23E73 for KRAS-Altered Advanced Tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental pill (JAB-23E73) for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink or slow the growth of these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a KRAS gene change (mutation or extra copies), and it must be advanced or spread to other parts of the body.
- You must be able to swallow pills whole.
- You must not have had prior treatment with a RAS-targeting drug (like sotorasib or adagrasib).
- You must not have untreated or growing brain metastases that are causing symptoms.
- You must be able to do your daily activities with little or no help (ECOG 0 or 1).
- You must have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
This study tests an experimental pill called JAB-21822 that targets a specific gene change (KRAS G12C) in advanced pancreatic cancer or other solid tumors. It's for people who have already tried standard chemotherapy and whose cancer has gotten worse or who couldn't handle the side effects.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
This trial tests a new drug called JAB-23E73 for people with advanced solid tumors that have a specific change in the KRAS gene. It may be an option if previous treatments have stopped working or are not suitable.
This study tests a new drug combined with chemotherapy for people with pancreatic cancer that has spread and has a KRAS gene mutation. It may help shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.